ClinicalTrials.gg
RecruitingNCT07847073Updated Oct 28, 2026

Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients

A Phase 4 interventional study of Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA] and Timolol Maleate 0.25% Ophthalmic Solution in Open Angle Glaucoma (OAG) and Glaucoma, sponsored by Brett King. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Brett King · Phase 4, Interventional, and Other

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.

Planned enrollment
15th of 17
13 · median 85
Started
2026
the only one that year
Phase 4
5 of 17
3 open now
Registered
17th of 17
by date
Lead sponsor
1 of 17
Brett King

Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 15th largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 4, and was the 17th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About netarsudil

netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing netarsudil in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The purpose of this study is to compare how two FDA-approved eye drops: netarsudil (Rhopressa) and timolol, protect nerve cells in the eye of adults with open-angle glaucoma. Both medications lower pressure inside the eye, but researchers want to learn if Rhopressa is more effective at slowing down or preventing the loss of retinal ganglion cells. These cells are essential for sight because they carry visual signals from the eye to the brain.

Participants in this study will complete a total of 6 study visits over 12 months:

  • Participants will spend 6 months using Rhopressa eye drops and 6 months using Timolol eye drops. The order of the two eye drops will be chosen randomly.
  • At scheduled study visits, researchers will examine participants' eyes and measure eye pressure.
  • Researchers will take detailed pictures of the back of the eye using a specialized high-resolution camera called adaptive optics optical coherence tomography (AO-OCT).
  • Participants will also complete specialized visual field testing to measure eye function.

Researchers will count and track individual nerve cells over time to determine if one medication offers better protection against cell loss than the other.

Read the detailed description

Glaucoma is a chronic, progressive optic neuropathy characterized by functional and structural alterations, specifically the degeneration and loss of retinal ganglion cells (RGCs). Currently, the main modifiable factor for intervention is aimed at lowering intraocular pressure (IOP). While IOP reduction slows disease progression, it does not halt neurodegeneration. Rho kinase (ROCK) inhibitors have been reported to provide benefit in neurodegenerative diseases. Netarsudil ophthalmic solution (Rhopressa) is a ROCK inhibitor approved for the treatment and management of open-angle glaucoma that lowers IOP and has reported protective effects on neural tissue. However, previous attempts to illustrate true cell loss or protection using clinical instrumentation have not demonstrated an effect to date.

High-resolution retinal imaging based on adaptive optics optical coherence tomography (AO-OCT) enables direct visualization, tracking, and quantification of individual ganglion cell layer (GCL) somas in the living human eye. Leveraging the unique imaging capabilities and extraordinary sensitivity of ultra-high-speed AO-OCT, this study will test the hypothesis that treatment with netarsudil is more effective at reducing glaucomatous ganglion cell loss while producing comparable intraocular pressure reduction to that of the comparator.

This prospective, randomized, investigator-masked, cross-over pilot study will compare RGC survival rates between two treatment groups (Rhopressa and Timolol). Thirteen subjects with open-angle glaucoma will be recruited. Following a screening assessment and medication washout period based on drug class, eligible subjects are randomized 1:1 into two age-matched cohorts:

  • Cohort 1: Receives Rhopressa (one drop once at night) for 6 months, then crosses over to receive Timolol 0.25% (one drop twice a day) for 6 months.
  • Cohort 2: Receives Timolol 0.25% (one drop twice a day) for 6 months, then crosses over to receive Rhopressa (one drop once at night) for 6 months.

At Visit 2 (baseline), Visit 4 (6 months), and Visit 6 (12 months), subjects undergo imaging using the Indiana AO-OCT system along with Goldmann applanation tonometry, standard clinical OCT, and OCT-guided microperimetry (MP-3). AO-OCT imaging is performed at the same retinal regions surrounding arcuate defects to enable longitudinal cellular-level analysis. Primary and secondary endpoints evaluate differences in the rate of change of RGC soma density, individual RGC counts, and GCL thickness between treatment periods.

03

Conditions studied

  • Open Angle Glaucoma (OAG)
  • Glaucoma

Keywords

  • glaucoma
  • rhopressa
  • ganglion cells
  • optometry
  • vision
  • IOP
  • eye pressure
  • timolol
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All subjects will be 18 years of age or older
  • Subjects must be diagnosed with open-angle glaucoma and have had an eye exam within the past year
  • Subjects with glaucoma will have structural (optic nerve and retinal nerve fiber layer) and functional (visual field testing) defects consistent with the diagnosis of glaucoma
  • Subjects will have a corrected acuity of 20/50 or better and be able to fixate
  • Naïve to medication subjects or post washout IOP between 18 and 34 mmHg
  • Spherical equivalent from +3 diopters to -6 diopters, with a cylinder of \<-3 diopters
  • Subject is willing and able to comply with the protocol requirements and to remain in the study for its full duration, including all scheduled visits and follow-up assessments

Exclusion criteria

Exclusion Criteria:

  • Subjects with a known intolerance to netarsudil ophthalmic solution
  • Subjects with a known intolerance to, or for, timolol maleate
  • Any subject whom the investigator determines to be at unacceptable risk for the or believes is unlikely to complete the study
  • Subjects with retinal disease or optic neuropathies other than glaucoma that, in the opinion of the investigator, could confound the study assessments or outcome
  • Female subjects who are pregnant, breastfeeding, or of childbearing age who are not sterile or using an acceptable method of during the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
13 participants (estimated)

Study arms

  • Experimental
    Rhopressa first, then Timolol

    Participants will instill netarsudil 0.02% (Rhopressa) ophthalmic solution (1 drop in the study eye once daily in the evening) for the first 6 months (Months 0-6). At the Month 6 visit, participants will cross over to instill timolol maleate 0.25% ophthalmic solution (1 drop in the study eye twice daily) for the remaining 6 months (Months 6-12).

    Drug: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA] · Drug: Timolol Maleate 0.25% Ophthalmic Solution

  • Experimental
    Timolol first, then Rhopressa

    Participants will instill timolol maleate 0.25% ophthalmic solution (1 drop in the study eye twice daily) for the first 6 months (Months 0-6). At the Month 6 visit, participants will cross over to instill netarsudil 0.02% (Rhopressa) ophthalmic solution (1 drop in the study eye once daily in the evening) for the remaining 6 months (Months 6-12).

    Drug: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA] · Drug: Timolol Maleate 0.25% Ophthalmic Solution

Interventions

  • Netarsudil ophthalmic solution (Rhopressa) is an FDA-approved Rho kinase inhibitor indicated for the treatment of ocular hypertension and open-angle glaucoma. In this study, participants will instill 1 drop of netarsudil 0.02% ophthalmic solution in the study eye once daily in the evening for 6 months.

    Also known as: Rhopressa

  • Timolol maleate ophthalmic solution is an FDA-approved non-selective beta-adrenergic receptor blocking agent indicated for the treatment of ocular hypertension and open-angle glaucoma. In this study, participants will instill 1 drop of timolol maleate 0.25% ophthalmic solution in the study eye twice daily (in the morning and evening) for 6 months.

    Also known as: Timoptic

06

What researchers measure

Primary outcomes

  1. Change in GC soma density (cells/mm²)

    Change in ganglion cell (GC) soma density during treatment with timolol versus netarsudil (Rhopressa)

    Time frame: Baseline, 6 months, and 12 months

Secondary outcomes

  1. Changes in GC soma counts (number of cells)

    Changes in ganglion cell (GC) soma counts during treatment with timolol versus netarsudil (Rhopressa)

    Time frame: Baseline, 6 months, and 12 months

  2. Changes in GCL thickness (micrometers (µm))

    Changes in ganglion cell layer (GCL) thickness during treatment with timolol versus netarsudil (Rhopressa)

    Time frame: Baseline, 6 months, and 12 months

07

Study locations

1 of 1 sites recruiting
  • Indiana University School Of Optometry
    Bloomington, Indiana 47405, United States
    Recruiting
    • Brett J King, OD, FAAO, Dipl AAO(Glaucoma) · Contactkingbrj@iu.edu · (812) 855-1344
    • Kaitlyn M Asher, CCRC, BS · Contactkamasher@iu.edu · 2194067487
    • Donald T Miller, PhD · Sub investigator
    • Matthew Keller, OD · Sub investigator
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jan 2028, 15 months later.

Of 45 phase 4 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartEst.
Oct 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 2 updates
  1. Oct 28, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and design details
  2. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07847073
Lead sponsor
Brett King
Collaborators
Alcon Research
Responsible party
Brett King (Clinical Professor, Indiana University) — Sponsor-investigator
First posted
Sep 29, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Brett J King, OD, FAAO, Dipl AAO (Glaucoma)
Contact
kingbrj@iu.edu
(812) 855-1344
Kaitlyn M Asher, CCRC, BS
Contact
kamasher@iu.edu
2194067487

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion